Pricing Log in Create free account

AgomAb Therapeutics NV (AGMB) vs Atea Pharmaceuticals, Inc. (AVIR)

AgomAb Therapeutics NV and Atea Pharmaceuticals, Inc. are both Biotechnology companies. AgomAb Therapeutics NV and Atea Pharmaceuticals, Inc. are of similar size ($343.3M and $338.5M). Across the 5 metrics below, Atea Pharmaceuticals, Inc. leads on 3 and AgomAb Therapeutics NV on 2.

Valuation

Metric AGMB AVIR Biotechnology median
P/E — n/m 10.60
P/S — 0.98 9.40
P/B n/m 1.68 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 0.35 9.02
Earnings yield — (48.48%) (32.88%)
Free cash flow yield 0.00% (160.13%) (23.13%)

Profitability

Metric AGMB AVIR Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity — (58.14%) (51.96%)
Return on assets — (52.99%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AGMB AVIR Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (39.80%) 3.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AGMB AVIR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.88 8.13 4.97
Net debt to EBITDA 1.96 1.63 1.01

Dividend

Metric AGMB AVIR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AGMB AVIR Biotechnology median
Market cap 343.27m 338.46m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack